

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Allen David Roses

Serial No.: 09/826,629

Examiner: Allen, Marianne P.

Filing Date: April 5, 2001

Art Unit: 1631

For: *Iterative Analysis of Non-responding
Population in the Design of
Pharmacogenetics Studies*Commissioner for Patents
Washington D.C. 20231# 7
Plunkett
12/18/02RESPONSE TO RESTRICTION

Sir:

This paper is submitted in response to the Office Action mailed September 25, 2002 (Paper No. 6) for which a 1 month shortened statutory period to respond was set. Accordingly, this paper is timely filed on or before October 25, 2002. Early examination of the application on the merits is earnestly solicited.

REMARKS

Claims 1-19 are pending in this application. The Examiner has required restriction to one of four groups. In response to such restriction Applicants wish to proceed as follows.

Applicants elect with traverse Group IV drawn to methods of developing a drug for different patients classified in Class 702, Subclass 20, claim 7, for proceeding with prosecution on the merits.

Applicants respectfully disagree with the subject restriction requirement and traverse as follows. The Examiner has not established that an unduly burdensome search and examination would be required in the present application. That is, it is believed that the Examiner has not established (1) separate classification, (2) separate status in the art, or (3) a different field of

12/18/2002 TTAB1 0000003 071392 09826629

1


01 FC:1252

400.00 CH

search for the subject matter of the various asserted inventions as required by M.P.E.P. 808.02. Applicants believe the present invention, as described, may be searched and examined without undue burden on the U.S. Patent Office. It is respectfully asserted that the Office Action has not provided a basis for asserting otherwise. Accordingly, Applicants respectfully request reconsideration of the restriction requirement.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Frank P. Grassler
Attorney for Applicants
Registration No. 31,164

Date: December 13, 2002
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-2482

DEC. 16. 2002 3:54PM GLAXO WELLCOME

NO. 6880 P. 1

FAX RECEIVED

DEC 17 2002

FAX

GROUP 1600



GlaxoSmithKline

To Examiner Allen, Marianne P., Group 1631
Company USPTO
Fax 703-872-9306 **OFFICIAL**
From Marjorie J. Pfeiffer
Tel 1-919-483-9038; Facsimile: 1-919-483-7988
E-mail Mjp14849@gsk.com
Date December , 2002 **Pages including cover** 7
Subject Response to Restriction Requirement

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Re: Response to Restriction Requirement and Extension of Time
Application of Allen David ROSES
U.S. Serial No.: 09/826,629; Filed: April 5, 2001
Examiner: Allen, Marianne P.; Group Art: 1631
Title: *Iterative Analysis of Non-responding Population
In the Design of Pharmacogenetics Studies*
Attorney Docket No. PU3948US2

Attached:

1. Certificate of Transmission (37 CFR 1.8(a))
2. Transmittal Form
3. Petition and Fee for Extension of Time (in duplicate)
4. Response to Restriction (2 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

DEC. 16, 2002 3:54PM

GLAXO WELLCOME

NO. 6880 P. 2

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

Applicant(s): Allen David ROSES

Docket No.

PU3948US2

Serial No.
09/826,629

Filing Dat
April 5, 2001

Examiner
Allen, Marianne P.

Group Art Unit
1631

Invention: **ITERATIVE ANALYSIS OF NON-RESPONDING POPULATION IN THE DESIGN OF
STUDIES PHARMACOGENETICS**

I hereby certify that this Response to Restriction with Extension of Time

(Identify type of correspondence)

is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-872-9306)

on DECEMBER 16, 2002
(Date)

Marjorie J. Pfeiffer

(Typed or Printed Name of Person Signing Certificate)

Marjorie J. Pfeiffer
(Signature)

Note: Each paper must have its own certificate of mailing.

Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

Application	09/826,629
Filing Date	April 5, 2001
First Named	Allen David ROSES
Group Art Unit	1631
Examiner Name	Allen, Marianne P.
Attorney Docket Number	PU3948US2

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	<input type="checkbox"/>
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/>
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	<input type="checkbox"/>
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Frank P. Grassler Registration No. 31,164 Telephone: (919) 483-2482
Signature	 23347
Date	December 13, 2002

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.